IL-2: The first effective immunotherapy for human cancer

Steven A. Rosenberg

Research output: Contribution to journalArticlepeer-review


The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding αβ TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.

Original languageEnglish (US)
Pages (from-to)5451-5458
Number of pages8
JournalJournal of Immunology
Issue number12
StatePublished - Jun 15 2014

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'IL-2: The first effective immunotherapy for human cancer'. Together they form a unique fingerprint.

Cite this